BeiGene (ONC) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-37686
Entity Registrant Name	BEIGENE, LTD.
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	98-1209416
Entity Address, Street Address	c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address Two	94 Solaris Avenue, Camana Bay
Entity Address, City	Grand Cayman
Entity Address, Country	KY
Entity Address, Postal Zip Code	KY1-1108
City Area Code	345
Local Phone Number	949-4123
Title of 12(b) Security	American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol	BGNE
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		1,008,198,947
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001651308
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 1,957,101	$ 618,011
Short-term restricted cash	282	288
Short-term investments	1,417,097	364,728
Accounts receivable, net	65,620	70,878
Inventories	28,775	28,553
Prepaid expenses and other current assets	126,312	90,238
Total current assets	3,595,187	1,172,696
Long-term restricted cash	2,435	2,476
Property, plant and equipment, net	240,331	242,402
Operating lease right-of-use assets	91,509	82,520
Intangible assets, net	5,563	5,846
Deferred tax assets	37,937	37,894
Other non-current assets	94,250	68,455
Total non-current assets	472,025	439,593
Total assets	4,067,212	1,612,289
Current liabilities:
Accounts payable	98,364	122,488
Accrued expenses and other payables	179,331	163,556
Tax payable	19,535	13,454
Operating lease liabilities, current portion	14,597	10,814
Research and development cost share liability, current portion	128,672	0
Short-term bank loan	11,298	0
Total current liabilities	451,797	310,312
Non-current liabilities:
Long-term bank loan	81,913	83,311
Shareholder loan	157,278	157,384
Operating lease liabilities, non-current portion	32,967	25,833
Deferred tax liabilities	10,368	10,532
Research and development cost share liability, non-current portion	460,528	0
Other long-term liabilities	45,305	46,562
Total non-current liabilities	788,359	323,622
Total liabilities	1,240,156	633,934
Commitments and contingencies
Equity:
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,007,976,816 and 801,340,698 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	101	79
Additional paid-in capital	5,138,239	2,925,970
Accumulated other comprehensive loss	(6,548)	(8,001)
Accumulated deficit	(2,319,578)	(1,955,843)
Total BeiGene, Ltd. shareholders’ equity	2,812,214	962,205
Noncontrolling interest	14,842	16,150
Total equity	2,827,056	978,355
Total liabilities and equity	$ 4,067,212	$ 1,612,289

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Ordinary shares
Ordinary shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized (in shares)	9,500,000,000	9,500,000,000
Ordinary shares, shares issued (in shares)	1,007,976,816	801,340,698
Ordinary shares, shares outstanding (in shares)	1,007,976,816	801,340,698

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues
Revenues	$ 52,059	$ 77,833
Expenses
Cost of sales - product	14,149	15,261
Research and development	304,302	178,351
Selling, general and administrative	107,081	57,645
Amortization of intangible assets	283	331
Total expenses	425,815	251,588
Loss from operations	(373,756)	(173,755)
Interest income, net	6,690	4,477
Other income, net	3,681	1,728
Loss before income taxes	(363,385)	(167,550)
Income tax expense	1,554	519
Net loss	(364,939)	(168,069)
Less: net loss attributable to noncontrolling interests	(1,204)	(429)
Net loss attributable to BeiGene, Ltd.	$ (363,735)	$ (167,640)
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	$ (0.36)	$ (0.22)
Weighted-average shares outstanding, basic and diluted (shares)	1,005,347,581	774,750,255
Net loss per American Depositary Share (“ADS”), basic and diluted (in dollars per share)	$ (4.70)	$ (2.81)
Weighted-average ADSs outstanding, basic and diluted (shares)	77,334,429	59,596,173
Product revenue, net
Revenues
Revenues	$ 52,059	$ 57,421
Collaboration revenue
Revenues
Revenues	$ 0	$ 20,412

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (364,939)	$ (168,069)
Other comprehensive (loss)/ income, net of tax of nil:
Foreign currency translation adjustments	(4,349)	3,755
Unrealized holding gain, net	5,698	685
Comprehensive loss	(363,590)	(163,629)
Less: comprehensive loss attributable to noncontrolling interests	(1,308)	(535)
Comprehensive loss attributable to BeiGene, Ltd.	$ (362,282)	$ (163,094)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Operating activities:
Net loss	$ (364,939)	$ (168,069)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	7,750	3,416
Share-based compensation expenses	38,255	26,392
Provision for doubtful accounts	2,022	0
Unrealized gain on equity securities	(6,964)	0
Acquired in-process research and development	43,000	29,000
Amortization of research and development cost share liability	(27,634)	0
Non-cash interest expense	2,572	1,858
Deferred income tax benefits	(206)	(983)
Other items, net	(1,105)	(3,218)
Changes in operating assets and liabilities:
Accounts receivable	3,236	(17,920)
Inventories	(222)	3,102
Prepaid expenses and other current assets	(36,075)	(5,772)
Operating lease right-of-use assets	(8,990)	(1,588)
Other non-current assets	(2,710)	(10,212)
Accounts payable	(21,450)	(20,364)
Accrued expenses and other payables	15,775	(8,790)
Tax payable	6,080	969
Deferred revenue	0	(2,238)
Operating lease liabilities	10,917	1,550
Other long-term liabilities	(1,256)	892
Net cash used in operating activities	(341,944)	(171,975)
Investing activities:
Purchases of property, plant and equipment	(21,533)	(21,828)
Purchases of investments	(1,307,179)	(487,354)
Proceeds from sale or maturity of investments	256,743	710,598
Purchase of in-process research and development	(43,000)	(29,000)
Net cash (used in) provided by investing activities	(1,114,969)	172,416
Financing activities:
Proceeds from sale of ordinary shares, net of cost	2,162,407	0
Proceeds from research and development cost share liability	616,834	0
Proceeds from long-term bank loan	0	36,695
Proceeds from short-term bank loan	11,298	0
Proceeds from option exercises and employee share purchase plan	11,629	6,269
Net cash provided by financing activities	2,802,168	42,964
Effect of foreign exchange rate changes, net	(6,212)	4,265
Net increase in cash, cash equivalents, and restricted cash	1,339,043	47,670
Cash, cash equivalents, and restricted cash at beginning of period	620,775	740,713
Cash, cash equivalents, and restricted cash at end of period	1,959,818	788,383
Supplemental cash flow information:
Cash and cash equivalents	1,957,101	764,492
Short-term restricted cash	282	14,900
Long-term restricted cash	2,435	8,991
Income taxes paid	531	360
Interest paid	1,136	888
Supplemental non-cash information:
Acquisitions of equipment included in accounts payable	$ 26,412	$ 32,462

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders' Equity Consolidated Statements Of Shareholders' Equity - USD ($) $ in Thousands	Total	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Noncontrolling Interests
Balance at the beginning of period at Dec. 31, 2018	$ 1,753,647	$ 1,739,202	$ 77	$ 2,744,814	$ 1,526	$ (1,007,215)	$ 14,445
Balance at the beginning of period (in shares) at Dec. 31, 2018			776,263,184
Increase (Decrease) in Stockholders' Equity
Issuance (use) of shares reserved for share option exercises (in shares)			(916,383)
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	6,269	6,269	$ 1	6,268
Exercise of options, ESPP and release of Restricted Share Units (RSUs) (in shares)			2,066,383
Share-based compensation	26,392	26,392		26,392
Other comprehensive income	4,440	4,546			4,546		(106)
Net loss	(168,069)	(167,640)				(167,640)	(429)
Balance at the ending of period (in shares) at Mar. 31, 2019			777,413,184
Balance at the end of period at Mar. 31, 2019	1,622,679	1,608,769	$ 78	2,777,474	6,072	(1,174,855)	13,910
Balance at the beginning of period at Dec. 31, 2019	$ 978,355	962,205	$ 79	2,925,970	(8,001)	(1,955,843)	16,150
Balance at the beginning of period (in shares) at Dec. 31, 2019	801,340,698		801,340,698
Increase (Decrease) in Stockholders' Equity
Issuance of ordinary shares in connection with collaboration	$ 2,162,407	2,162,407	$ 21	2,162,386
Issuance of ordinary shares in connection with collaboration (in shares)			206,635,013
Issuance (use) of shares reserved for share option exercises (in shares)			(3,705,468)
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	11,629	11,629	$ 1	11,628
Exercise of options, ESPP and release of Restricted Share Units (RSUs) (in shares)			3,706,573
Share-based compensation	38,255	38,255		38,255
Other comprehensive income	1,349	1,453			1,453		(104)
Net loss	$ (364,939)	(363,735)				(363,735)	(1,204)
Balance at the ending of period (in shares) at Mar. 31, 2020	1,007,976,816		1,007,976,816
Balance at the end of period at Mar. 31, 2020	$ 2,827,056	$ 2,812,214	$ 101	$ 5,138,239	$ (6,548)	$ (2,319,578)	$ 14,842

Description of Business, Basis

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies	Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies Description of business BeiGene, Ltd. (the “Company”) is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. The Company started as a research and development company in Beijing in 2010. Over the last ten years, it has developed into a fully-integrated global biotechnology company, with significant commercial, manufacturing, and research and development capabilities. The Company has built substantial commercial capabilities in China and the United States and is currently marketing both internally-developed drugs and in-licensed drugs. In the United States, the Company markets BRUKINSA ™ (zanubrutinib) for adult patients with mantle cell lymphoma ("MCL") who have received at least one prior therapy. In China, the Company markets tislelizumab for patients with classical Hodgkin’s Lymphoma ("cHL") who have received at least two prior therapies and for patients with locally advanced or metastatic urothelial carcinoma ("UC"), a form of bladder cancer, with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. As of May 1, 2020, the Company has filed three additional new or supplementary new drug applications ("sNDA") for regulatory approvals in China for its internally-developed products and is planning for launches in these additional products or indications in 2020 and beyond. The Company's in-licensed portfolio includes ABRAXANE ® , REVLIMID ® and VIDAZA ® , which it has been marketing in China since 2017 under a license from Celgene Logistics Sàrl, a Bristol Myers Squibb (“BMS”) company. The Company plans on launching additional in-licensed products in China from its collaborations, including XGEVA ® (denosumab), KYPROLIS ® (carfilzomib) and BLINCYTO ® (blinatumomab) from Amgen Inc. ("Amgen"), and SYLVANT ® (siltuximab) and QARZIBA ® ▼ (dinutuximab beta), from EUSA Pharma ("EUSA"). Basis of presentation and consolidation The accompanying condensed consolidated balance sheet as of March 31, 2020 , the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2020 and 2019 , the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 , and the condensed consolidated statements of shareholders' equity for the three months ended March 31, 2020 and 2019 , and the related footnote disclosures are unaudited. The accompanying unaudited interim financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the "Annual Report"). The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of the operations for the three months ended March 31, 2020 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. The condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Noncontrolling interests are recognized to reflect the portion of the equity of subsidiaries which are not attributable, directly or indirectly, to the controlling shareholders. The Company consolidates its interests in its joint venture, BeiGene Biologics Co., Ltd. ("BeiGene Biologics") and MapKure, LLC, under the voting model and recognizes the minority shareholders' equity interest as a noncontrolling interest in its condensed consolidated financial statements. Use of estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company’s revenue arrangements, estimating the fair value of net assets acquired in business combinations, assessing the impairment of long-lived assets, share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates. Recent accounting pronouncements New accounting standards which have been adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses . Subsequently, the FASB issued ASU 2019-05, Financial Instruments- Credit Losses (Topic 326): Targeted Transition Relief and ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments- Credit Losses (collectively, the "Credit Loss ASUs"). The Credit Loss ASUs change the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The Company adopted the standard on January 1, 2020. Based on the composition of the Company's trade receivables and investment portfolio, the adoption of this standard did not have a material impact on the Company’s financial position or results of operations upon adoption. The Company has updated its accounting policy for trade accounts receivable and is providing additional disclosure about its allowance for credit losses, as required by the standard, upon adoption. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement . The update eliminates, modifies, and adds certain disclosure requirements for fair value measurements. The added disclosure requirements and the modified disclosure on the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented. All other changes to disclosure requirements in this update should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard on January 1, 2020. There was no material impact to the Company's financial position or results of operations upon adoption. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract . This update requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. This guidance should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company adopted this standard on January 1, 2020. There was no material impact to the Company's financial position or results of operations upon adoption. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 . This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Company adopted this standard on January 1, 2020. There was no material impact to the Company's financial position or results of operations upon adoption. New accounting standards which have not yet been adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This update simplifies the accounting for income taxes as part of the FASB's overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, Income taxes , and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2020, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, and all other amendments should be applied prospectively. The Company is currently evaluating the impact on its financial statements of adopting this guidance. Significant accounting policies For a more complete discussion of the Company’s significant accounting policies and other information, the condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2019 . Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company's current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer's ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased. Except for the changes to the Company’s significant accounting policies related to the adoption of the Credit Loss ASUs, there have been no other material changes to the Company’s significant accounting policies as of and for the three months ended March 31, 2020 , as compared to the significant accounting policies described in the Annual Report.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in market with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability. The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and considers an inactive market to be one in which there are infrequent or few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. The following tables present the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of March 31, 2020 and December 31, 2019 : Quoted Price in Active Significant Market for Other Significant Identical Observable Unobservable Assets Inputs Inputs As of March 31, 2020 (Level 1) (Level 2) (Level 3) $ $ $ Short-term investments (Note 4): U.S. treasury securities 1,417,097 — — Cash equivalents: U.S. treasury securities 251,505 — — Money market funds 1,144,458 — — Other non-current assets: Equity securities (Note 4) 7,592 4,372 — Total 2,820,652 4,372 — Quoted Price in Active Significant Market for Other Significant Identical Observable Unobservable Assets Inputs Inputs As of December 31, 2019 (Level 1) (Level 2) (Level 3) $ $ $ Short-term investments (Note 4): U.S. treasury securities 364,728 — — Cash equivalents U.S. treasury securities 16,442 — — Money market funds 50,461 — — Total 431,631 — — The Company's equity securities consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. ("Leap"), which were acquired in connection with a strategic collaboration and license agreement entered into in January 2020. The common stock investment in Leap, a publicly-traded biotechnology company, is measured and carried at fair value and classified as Level 1. The warrants to purchase additional shares of common stock in Leap are classified as a Level 2 investment and are measured using the Black-Scholes option-pricing valuation model, which utilizes a constant maturity risk-free rate and reflects the term of the warrants, dividend yield and stock price volatility, that is based on the historical volatility of similar companies. The Company had no liabilities measured and recorded at fair value on a recurring basis as of March 31, 2020 or December 31, 2019

Collaborative Arrangements

Collaborative Arrangements	3 Months Ended
	Mar. 31, 2020
Research and Development [Abstract]
Collaborative Arrangements	Collaborative Arrangements The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of internally-developed drug candidates to other parties, in-licenses of drug products and drug candidates from other parties, and profit and cost sharing arrangements. Amgen On October 31, 2019, the Company entered into a global strategic oncology collaboration with Amgen (the "Amgen Collaboration Agreement") for the commercialization and development in China, excluding Hong Kong, Taiwan and Macao, of Amgen’s XGEVA, KYPROLIS, and BLINCYTO, and the joint global development of a portfolio of oncology assets in Amgen’s pipeline, with BeiGene responsible for development and commercialization in China. On January 2, 2020, following approval by the Company's shareholders and satisfaction of other closing conditions, the agreement became effective. Under the agreement, the Company is responsible for the commercialization of XGEVA, KYPROLIS and BLINCYTO in China for five or seven years. Amgen is responsible for manufacturing of the products globally and will supply the products to the Company at an agreed upon price. The Company and Amgen will share equally in the China commercial profits and losses during the commercialization period. Following the commercialization period, the Company has the right to retain one product and is entitled to receive royalties on sales in China for an additional five years on the products not retained. XGEVA was approved in China in 2019 for patients with giant cell tumor of the bone and a supplemental new drug application has been filed for prevention of skeletal-related events in cancer patients with bone metastases. Additionally, new drug applications have been filed in China for KYPROLIS as a treatment for patients with multiple myeloma and BLINCYTO a as a treatment for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Amgen and the Company are also jointly developing a portfolio of Amgen oncology pipeline assets under the collaboration. In April 2020, two Amgen oncology pipeline assets were removed from the collaboration due to portfolio prioritization, and the parties expect that the development plan for the assets in the portfolio will continue to evolve over time. The Company is responsible for conducting clinical development activities in China and co-funding global development costs by contributing cash and development services up to a total cap of $1,250,000 . Amgen is responsible for all development, regulatory and commercial activities outside of China. For each pipeline asset that is approved in China, the Company will receive commercial rights for seven years from approval. The Company has the right to retain approximately one out of every three approved pipeline assets, other than AMG 510, for commercialization in China. The Company and Amgen will share equally in the China commercial profits and losses during the commercialization period. The Company is entitled to receive royalties from sales in China for pipeline assets returned to Amgen for five years after the seven-year commercialization period. The Company is also entitled to receive royalties from global sales of each product outside of China (with the exception of AMG 510). The Amgen Collaboration Agreement is within the scope of ASC 808, as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company is the principal for product sales to customers in China during the commercialization period and will recognize 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales will be recorded as cost of sales. Cost reimbursements due to or from Amgen under the profit share will be recognized as incurred and recorded to cost of sales; selling, general and administrative expense; or research and development expense, based on the underlying nature of the related activity subject to reimbursement. Costs incurred for the Company's portion of the global co-development funding are recorded to research and development expense as incurred. In connection with the collaboration, a Share Purchase Agreement ("SPA") was entered into by the parties on October 31, 2019. On January 2, 2020, the closing date of the transaction, Amgen purchased 15,895,001 of the Company's ADSs for $174.85 per ADS, representing a 20.5% ownership stake in the Company. Per the SPA, the cash proceeds shall be used as necessary to fund the Company's development obligations under the Amgen Collaboration Agreement. Pursuant to the SPA, Amgen also received the right to designate one member of the Company's board of directors. In determining the fair value of the common stock at closing, the Company considered the closing price of the common stock on the closing date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the shares on the closing date was determined to be $132.74 per ADS, or $2,109,902 in the aggregate. The Company determined that the premium paid by Amgen on the share purchase represents a cost share liability due to the Company's co-development obligations. The fair value of the cost share liability on the closing date was determined to be $601,857 based on the Company's discounted estimated future cash flows related to the pipeline assets. The total cash proceeds of $2,779,241 were allocated based on the relative fair value method, with $2,162,407 recorded to equity and $616,834 recorded as a research and development cost share liability. The cost share liability is being amortized proportionately as the Company contributes cash and development services to its total co-development funding cap. Amounts recorded related to the cash proceeds received from the Amgen collaboration for the three months ended March 31, 2020 were as follows: Three Months Ended March 31, 2020 $ Fair value of equity issued to Amgen 2,162,407 Fair value of research and development cost share liability 616,834 Total cash proceeds 2,779,241 Amounts recorded related to the Company's portion of the co-development funding on the pipeline assets for the three months ended March 31, 2020 were as follows: Three Months Ended March 31, 2020 $ Research and development expense 28,366 Amortization of research and development cost share liability 27,634 Total amount due to Amgen for BeiGene's portion of the development funding 56,000 Total amount of development funding payable in cash 56,000 Total amount of development funding paid with development services — Remaining portion of development funding cap at March 31, 2020 1,194,000 At March 31, 2020 , the research and development cost share liability recorded in the Company's balance sheet was as follows: As of March 31, 2020 $ Research and development cost share liability, current portion 128,672 Research and development cost share liability, non-current portion 460,528 Total research and development cost share liability 589,200 There were no product sales or commercial profit share payments related to the Amgen collaboration during the three months ended March 31, 2020 . Celgene Corporation, a Bristol Myers Squibb company ("BMS") On July 5, 2017, the Company entered into a license agreement with Celgene Corporation, now BMS, pursuant to which the Company granted to the BMS parties an exclusive right to develop and commercialize the Company’s investigational PD-1 inhibitor, tislelizumab, in all fields of treatment, other than hematology, in the United States, Europe, Japan and the rest of world other than Asia (the “PD-1 License Agreement”). The Company entered into a mutual agreement with BMS to terminate the Amended and Restated PD-1 License Agreement effective June 14, 2019 in advance of the acquisition of Celgene by BMS. The following table summarizes total collaboration revenue recognized related to the BMS collaboration for the three months ended March 31, 2020 and 2019 : Three Months Ended March 31, 2020 2019 $ $ Reimbursement of research and development costs — 18,174 Research and development service revenue — 2,238 Total — 20,412 For the three months ended March 31, 2019 , the Company recognized collaboration revenue of $20,412 related to its former collaboration with BMS. The Company recognized $18,174 of research and development reimbursement revenue for the three months ended March 31, 2019 for the clinical trials that Celgene had opted into. The $2,238 of research and development services revenue for the three months ended March 31, 2019 , reflected the recognition of upfront consideration that was allocated to research and development services at the time of the collaboration and was recognized over the term of the respective clinical studies for the specified indications. In-Licensing Arrangements The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates and drug products globally or in specific territories. These arrangements typically include non-refundable, upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost sharing arrangements, royalty payments, and profit sharing. Upfront and development milestones paid under these arrangements for the three months ended March 31, 2020 and 2019 are set forth below. All upfront and development milestones were expensed to research and development expense. There have been no regulatory or commercial milestones paid under these arrangements to date. Three Months Ended March 31, 2020 2019 Research and development payments to Collaboration Partners $ $ Upfront payments 43,000 10,000 Milestone payments 5,000 — Total 48,000 10,000 EUSA Pharma On January 13, 2020, the Company entered into an exclusive development and commercialization agreement with EUSA Pharma ("EUSA") for the orphan biologic products SYLVANT ® (siltuximab) and QARZIBA ® (dinutuximab beta) in China. Under the terms of the agreement, EUSA granted the Company exclusive rights to SYLVANT in greater China and to QARZIBA in mainland China. Under the agreement, the Company will fund and undertake all clinical development and regulatory submissions in the territories, and will commercialize both products once approved. EUSA received a $40,000 upfront payment and will be eligible to receive payments upon the achievement of regulatory and commercial milestones up to a total of $160,000 . EUSA will also be eligible to receive tiered royalties on future product sales. The upfront payment was expensed to research and development expense during the three months ended March 31, 2020 in accordance with the Company's acquired in-process research and development expense policy. Other In addition to the collaborations discussed above, the Company has entered into additional collaborative arrangements during the three months ended March 31, 2020 and 2019 . The Company may be required to pay additional amounts upon the achievement of various development, regulatory and commercial milestones under these agreements. The Company may also incur significant research and development costs if the related product candidates advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay milestones and royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.

Restricted Cash and Investments

Restricted Cash and Investments	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Restricted Cash and Investments	Restricted Cash and Investments Restricted Cash The Company’s restricted cash balance of $2,717 as of March 31, 2020 primarily consists of RMB-denominated cash deposits held in designated bank accounts for collateral for letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction. Short-Term Investments Short-term investments as of March 31, 2020 consisted of the following available-for-sale debt securities: Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) $ $ $ $ U.S. treasury securities 1,410,129 6,968 — 1,417,097 Total 1,410,129 6,968 — 1,417,097 Short-term investments as of December 31, 2019 consisted of the following available-for-sale debt securities: Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) $ $ $ $ U.S. treasury securities 363,440 1,288 — 364,728 Total 363,440 1,288 — 364,728 As of March 31, 2020

Inventories

Inventories	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories The Company’s inventory balance consisted of the following: As of March 31, December 31, 2020 2019 $ $ Work in process 444 — Finished goods 28,331 28,553 Total inventories 28,775 28,553

Property, plant and equipment

Property, plant and equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment Property, plant and equipment are recorded at cost and consisted of the following: As of March 31, December 31, 2020 2019 $ $ Laboratory equipment 49,059 47,154 Leasehold improvements 23,866 24,008 Building 107,992 109,514 Manufacturing equipment 65,123 62,775 Software, electronics and office equipment 14,688 14,705 Property, plant and equipment, at cost 260,728 258,156 Less accumulated depreciation (43,375 ) (36,709 ) Construction in progress 22,978 20,955 Property, plant and equipment, net 240,331 242,402 As of March 31, 2020 and December 31, 2019 , construction in progress ("CIP") of $22,978 and $20,955 , respectively, was primarily related to the buildout of additional capacity at the Guangzhou manufacturing facility. Subsequent phases of the Guangzhou factory buildout will continue to be recorded as CIP until they are placed into service. Depreciation expense for the three months ended March 31, 2020 and 2019 was $7,467 and $3,085 , respectively.

Guangzhou Biologics Business

Guangzhou Biologics Business	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Guangzhou Biologics Business	Guangzhou Biologics Business Manufacturing legal entity structure BeiGene (Shanghai) Co., Ltd. ("BeiGene Shanghai"), originally established as a wholly-owned subsidiary of BeiGene (Hong Kong) Co., Limited ("BeiGene HK"), and currently a wholly-owned subsidiary of BeiGene Biologics, as described below, provides clinical development services for BeiGene affiliates and is the clinical trial authorization ("CTA") holder and marketing authorization application ("MAA") holder for tislelizumab in China. In March 2017, BeiGene HK, a wholly-owned subsidiary of the Company, and Guangzhou GET Technology Development Co., Ltd. (now Guangzhou High-tech Zone Technology Holding Group Co., Ltd.) (“GET”) entered into a definitive agreement to establish a commercial-scale biologics manufacturing facility in Guangzhou, Guangdong Province, PRC. In March 2017, BeiGene HK and GET entered into an Equity Joint Venture Contract (the “JV Agreement”). Under the terms of the JV Agreement, BeiGene HK made an initial cash capital contribution of RMB 200,000 and a subsequent contribution of one or more biologics assets in exchange for a 95% equity interest in BeiGene Biologics. GET made a cash capital contribution of RMB 100,000 to BeiGene Biologics, representing a 5% equity interest in BeiGene Biologics. In addition, on March 7, 2017, BeiGene Biologics entered into a contract with GET, under which GET agreed to provide a RMB 900,000 loan (the “Shareholder Loan”) to BeiGene Biologics (see Note 12). In September 2019, BeiGene Biologics completed the first phase of construction of a biologics manufacturing facility in Guangzhou, through a wholly-owned subsidiary, BeiGene Guangzhou Biologics Manufacturing Co., Ltd. ("BeiGene Guangzhou Factory"), to manufacture biologics for the Company and its subsidiaries. In April 2017, BeiGene HK, GET and BeiGene Biologics amended the JV Agreement and the capital contribution agreement, among other things, to adjust the capital contribution schedules and adjust the initial term of the governing bodies and a certain management position. In the second quarter of 2017, BeiGene HK made cash capital contributions of RMB 137,830 and RMB 2,415 , respectively, into BeiGene Biologics. The remainder of the cash capital contribution from BeiGene HK to BeiGene Biologics was paid in June 2019. In April 2017, GET made cash capital contributions of RMB 100,000 into BeiGene Biologics, and BeiGene Biologics drew down the Shareholder Loan of RMB 900,000 from GET (as further described in Note 12). In the fourth quarter of 2017, BeiGene HK and BeiGene Biologics entered into an Equity Transfer Agreement to transfer 100% of the equity interest of BeiGene Shanghai to BeiGene Biologics, as required by the JV agreement, such that the CTA holder and MAA holder for tislelizumab in China was controlled by BeiGene Biologics. The transfer consideration for the purchased interests under this Equity Transfer Agreement is the fair value of the 100% equity of BeiGene Shanghai appraised by a qualified Chinese valuation firm under the laws of the PRC. Upon the transfer of equity in BeiGene Shanghai, BeiGene HK’s equity interest in BeiGene Shanghai became 95% . As of March 31, 2020 , the Company and GET held 95% and 5% equity interests in BeiGene Biologics, respectively. As of March 31, 2020 , the Company had $83,126 of cash and cash equivalents and $1,961 of restricted cash held by BeiGene Biologics to be used to build the commercial-scale biologics facility and to fund research and development of the Company's biologics drug candidates in China. Commercial distribution legal entity structure BeiGene (Guangzhou) Co., Ltd. (“BGC”), a wholly-owned subsidiary of BeiGene HK, was organized on July 11, 2017. In September 2018, BGC acquired 100% of the equity interests of Baiji Shenzhou (Guangzhou) Pharmaceuticals Co., Ltd. (formerly known as Huajian Pharmaceuticals Co., Ltd.), which subsequently changed its name to BeiGene Pharmaceuticals (Guangzhou) Co., Ltd. (“BPG”). BPG owns drug distribution licenses necessary to distribute pharmaceutical products in China. The Company acquired these drug distribution licenses through the acquisition of BPG, which was accounted for as an asset acquisition, as it is difficult to obtain a newly issued domestic drug distribution license in China. Commercial supply agreement and facility expansion In January 2018, the Company entered into a commercial supply agreement with Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (“Boehringer Ingelheim”) for tislelizumab, which is being manufactured at Boehringer Ingelheim’s facility in Shanghai, China as part of a Marketing Authorization Holder (“MAH”) project pioneered by the Company and Boehringer Ingelheim. Under the terms of the commercial supply agreement, Boehringer Ingelheim has agreed to manufacture tislelizumab in China under an exclusive multi-year arrangement, with contract extension possible. In addition, the Company obtained certain preferred rights for future capacity expansion by Boehringer Ingelheim in China. In October 2018, the Company entered into a binding letter of intent ("LOI") with Boehringer Ingelheim to increase the amount of tislelizumab supplied under the agreement through the expansion of Boehringer Ingelheim's facility to add a second bioreactor production line. Under the terms of the binding LOI, the Company provided initial funding for the facility expansion and may make additional payments for contingency costs. This initial funding payment and any subsequent contingency payments will be credited against future purchases of tislelizumab over the term of the supply agreement. The payment was recorded as a noncurrent asset since it is considered a long-term prepayment for future product costs that will provide future benefit to the Company through credits on purchases of tislelizumab from Boehringer Ingelheim over the life of the supply agreement.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets as of March 31, 2020 and December 31, 2019 are summarized as follows: As of March 31, 2020 December 31, 2019 Gross Gross carrying Accumulated Intangible carrying Accumulated Intangible amount amortization assets, net amount amortization assets, net $ $ $ $ $ $ Finite-lived intangible assets: Product distribution rights 7,500 (1,937 ) 5,563 7,500 (1,750 ) 5,750 Trading license 816 (816 ) — 816 (720 ) 96 Total finite-lived intangible assets 8,316 (2,753 ) 5,563 8,316 (2,470 ) 5,846 Product distribution rights consist of distribution rights on the approved cancer therapies licensed from BMS, ABRAXANE, REVLIMID, and VIDAZA acquired as part of the BMS transaction in 2017. The Company is amortizing the product distribution rights over a period of 10 years which is the term of the agreement. The trading license represents the Guangzhou drug distribution license acquired on September 21, 2018. The Company amortized the drug distribution trading license over the remainder of the initial license term through February 2020. Amortization expense of intangible assets for the three months ended March 31, 2020 and 2019 was $283 and $331 , respectively. As of March 31, 2020 , expected amortization expense for the unamortized finite-lived intangible assets is approximately $563 for the remainder of 2020 , $750 in 2021 , $750 in 2022 , $750 in 2023 , $750 in 2024 , and $2,000 in 2025 and thereafter.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax expense was $1,554 and $519 , respectively, for the three months ended March 31, 2020 and 2019. The income tax expense for the three months ended March 31, 2020 was primarily attributable to income reported in certain China subsidiaries as adjusted for certain non-deductible expenses offset by the tax benefit of deferred U.S. stock-based compensation deductions. The resulting current U.S. tax was reduced by windfall stock compensation deductions, research and development tax credits and other special tax deductions. The income tax expense for the three months ended March 31, 2019 was primarily attributable to income reported in the U.S. and certain China subsidiaries offset by U.S. research and development tax credits and other special tax deductions. In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law on March 27, 2020. The CARES Act removes certain net operating loss deduction and carry-back limitations originally imposed by the Tax Cuts and Jobs Act of 2017. Specifically, the Company may now carry back net operating losses (NOLs) originating in 2018 and 2019 to 2017 and 2016, resulting in an increase to the Company's income tax receivable of $5,586 as of March 31, 2020. The enactment of the CARES Act did not have a material effect on our income tax expense. On a quarterly basis, the Company evaluates the realizability of deferred tax assets by jurisdiction and assesses the need for a valuation allowance. In assessing the realizability of deferred tax assets, the Company considers historical profitability, evaluation of scheduled reversals of deferred tax liabilities, projected future taxable income and tax-planning strategies. Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After consideration of all positive and negative evidence, the Company believes that as of March 31, 2020 , it is more likely than not that deferred tax assets will not be realized for the Company’s subsidiaries in Australia and Switzerland, for certain subsidiaries in China, and for all U.S. tax credit carry-forwards. As of March 31, 2020 , the Company had gross unrecognized tax benefits of $5,003 . The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months. The Company’s reserve for uncertain tax positions increased by $369 in the three months ended March 31, 2020 primarily due to U.S. federal and state tax credits and incentives. The Company has elected to record interest and penalties related to income taxes as a component of income tax expense. As of March 31, 2020 and December 31, 2019 , the Company's accrued interest and penalties, where applicable, related to uncertain tax positions were not material. The Company conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of March 31, 2020 , Australia tax matters are open to examination for the years 2013 through 2020, China tax matters are open to examination for the years 2014 through 2020, Switzerland tax matters are open to examination for the years 2017 through 2020, and U.S. federal tax matters are open to examination for years 2015 through 2020. Various U.S. states and other non-US tax jurisdictions in which the Company files tax returns remain open to examination for 2010 through 2020.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information The roll-forward of the allowance for credit losses related to trade accounts receivable for the three months ended March 31, 2020 consists of the following activity: Allowance for Credit Losses $ Balance as of December 31, 2019 — Current period provision for expected credit losses 2,022 Amounts written-off — Recoveries of amounts previously written-off — Balance as of March 31, 2020 2,022 Prepaid expenses and other current assets consist of the following: As of March 31, December 31, 2020 2019 $ $ Prepaid research and development costs 75,867 69,715 Prepaid taxes 17,392 9,498 Other receivables 6,414 — Interest receivable 5,941 1,932 Prepaid insurance 4,298 — Prepaid manufacturing costs 3,525 — Other 12,875 9,093 Total 126,312 90,238 Other non-current assets consist of the following: As of March 31, December 31, 2020 2019 $ $ Goodwill 109 109 Prepayment of property and equipment 20,421 10,289 Prepayment of facility capacity expansion activities (1) 25,963 24,881 Prepaid VAT 32,396 29,967 Rental deposits and other 3,397 3,209 Long-term investment (Note 4) 11,964 — Total 94,250 68,455 (1) Represents payments for facility expansions under commercial supply agreements. The payments will provide future benefit to the Company through credits on future supply purchases as further described in Note 7. Accrued expenses and other payables consist of the following: As of March 31, December 31, 2020 2019 $ $ Compensation related 27,272 54,156 External research and development activities related 53,428 62,794 Development funding payable- Amgen 56,000 — Commercial activities 18,522 25,645 Income tax and other taxes 11,944 9,648 Sales rebates and returns related 4,014 3,198 Professional fees and other 8,151 8,115 Total 179,331 163,556 Other long-term liabilities consist of the following: As of March 31, December 31, 2020 2019 $ $ Deferred government grant income 45,134 46,391 Other 171 171 Total 45,305 46,562

Bank Loans

Bank Loans	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Bank Loans	Bank Loans On April 4, 2018, BeiGene Guangzhou Factory entered into a nine -year loan agreement with China Construction Bank to borrow an RMB denominated loan of RMB 580,000 at a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The loan is secured by BeiGene Guangzhou Factory’s land use right. Interest expense is paid quarterly until the loan is fully settled. As of March 31, 2020 , the Company has fully drawn down $81,913 (RMB 580,000 ) of the loan. The loan interest rate was 4.9% for the three months ended March 31, 2020 , and the maturity dates range from 2021 to 2027. On January 13, 2020, BeiGene Shanghai entered into a one -year loan agreement with China Industrial Bank to borrow up to RMB 200,000 at a fixed interest rate of 5.6% . On January 19, 2020, the Company borrowed RMB 80,000 of the loan. Interest will be paid quarterly until the loan becomes fully due on January 18, 2021. As of March 31, 2020 the amount outstanding under the loan agreement was $11,298 . Interest expense recognized for the three months ended March 31, 2020 and 2019 was $1,719 and $941 , respectively, among which, $66 and $641 was capitalized, respectively.

Shareholder Loan

Shareholder Loan	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Shareholder Loan	Shareholder Loan On March 7, 2017, BeiGene Biologics entered into the Shareholder Loan Contract with GET, pursuant to which GET agreed to provide a Shareholder Loan of RMB 900,000 to BeiGene Biologics. The Shareholder Loan has a conversion feature, settled in a variable number of shares of common stock upon conversion (the “debt-to-equity conversion”). On April 14, 2017, BeiGene Biologics drew down the entire Shareholder Loan of RMB 900,000 from GET. Key features of the Shareholder Loan The Shareholder Loan bears simple interest at a fixed rate of 8% per annum. No interest payment is due or payable prior to the repayment of the principal or the debt-to-equity conversion. The term of the Shareholder Loan is 72 months , commencing from the actual drawdown date of April 14, 2017 and ending on April 13, 2023, unless converted earlier. The Shareholder Loan may be repaid or converted, either partially or in full, into an additional mid-single digit percentage equity interest in BeiGene Biologics prior to its maturity date, pursuant to the terms of the JV Agreement. BeiGene Biologics has the right to make early repayment at any time; provided, however, that if repayment is to occur before the debt-to-equity conversion it would require written approval of both BeiGene Biologics and GET. Upon conversion of the Shareholder Loan, GET will receive an additional equity interest in BeiGene Biologics, which will be based on the formula outlined in the JV Agreement. The Shareholder Loan can only be used for BeiGene Biologics, including the construction and operation of the biologics manufacturing facility and research and development and clinical trials to be carried out by BeiGene Biologics. If BeiGene Biologics does not use the Shareholder Loan proceeds for the specified purposes, GET may be entitled to certain liquidated damages. In the event of an early termination of the JV Agreement, the Shareholder Loan will become due and payable at the time of termination of the JV Agreement. Accounting for the Shareholder Loan The Shareholder Loan is classified as a long-term liability and initially measured at the principal of RMB 900,000 . Interest is accrued based on the interest rate of 8% per annum. As the Shareholder Loan may be share-settled by a number of shares with a fair value equal to a fixed settlement amount, the settlement is not viewed as a conversion feature, but as a redemption feature because the settlement amount does not vary with the share price. This in-substance redemption feature does not require bifurcation because it is clearly and closely related to the debt host that does not involve a substantial premium or discount. Since there is no conversion feature embedded in the Shareholder Loan, no beneficial conversion feature was recorded. There are no other embedded derivatives that are required to be bifurcated. The portion of interest accrued on the Shareholder Loan related to borrowings used to construct the BeiGene factory in Guangzhou is being capitalized in accordance with ASC 835-20, Interest – Capitalization of Interest. For the three months ended March 31, 2020 and 2019, total interest generated from the Shareholder Loan was $2,572 and $2,645 , respectively, of which, $0 and $788 was capitalized, respectively.

Product Revenue

Product Revenue	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Product Revenue	Product Revenue The Company’s product sales are derived from the sale of its internally-developed products BRUKINSA in the U.S. and tislelizumab in China, as well as the sale of ABRAXANE, REVLIMID, and VIDAZA in China under a distribution license from BMS. The table below presents the Company’s net product sales for the three months ended March 31, 2020 and 2019 . Three Months Ended March 31, 2020 2019 $ $ Product revenue – gross 53,188 58,536 Less: Rebates and sales returns (1,129 ) (1,115 ) Product revenue – net 52,059 57,421 The following table disaggregates net product sales by product for the three months ended March 31, 2020 and March 31, 2019 : Three Months Ended March 31, 2020 2019 $ $ Tislelizumab 20,526 — BRUKINSA ™ 717 — ABRAXANE ® 17,145 27,134 REVLIMID ® 7,628 23,584 VIDAZA ® 6,043 6,703 Total net product revenue 52,059 57,421 The following table presents the roll-forward of accrued sales rebates and returns for the three months ended March 31, 2020 and March 31, 2019 : Sales Rebates and Returns $ Balance as of December 31, 2019 4,749 Accrual 1,115 Payments (2,498 ) Balance as of March 31, 2019 3,366 Balance as of December 31, 2019 3,198 Accrual 1,129 Payments (313 ) Balance as of March 31, 2020 4,014

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Loss Per Share	Loss Per Share Loss per share was calculated as follows: Three Months Ended March 31, 2020 2019 $ $ Numerator: Net loss attributable to BeiGene, Ltd. (363,735 ) (167,640 ) Denominator: Weighted average shares outstanding, basic and diluted 1,005,347,581 774,750,255 Net loss per share attributable to BeiGene, Ltd., basic and diluted (0.36 ) (0.22 ) The effects of all share options, restricted shares and restricted share units were excluded from the calculation of diluted loss per share, as their effect would have been anti-dilutive during the three months ended March 31, 2020 and 2019 .

Share-Based Compensation Expens

Share-Based Compensation Expense	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Expense	Share-Based Compensation Expense 2016 Share Option and Incentive Plan On January 14, 2016, in connection with the Company's initial public offering ("IPO") on the NASDAQ Stock Market, the board of directors and shareholders of the Company approved the 2016 Share Option and Incentive Plan (the “2016 Plan”), which became effective on February 2, 2016. The Company initially reserved 65,029,595 ordinary shares for the issuance of awards under the 2016 Plan, plus any shares available under the 2011 Option Plan (the “2011 Plan”), and not subject to any outstanding options as of the effective date of the 2016 Plan, along with underlying share awards under the 2011 Plan that are cancelled or forfeited without issuance of ordinary shares. As of March 31, 2020 , ordinary shares cancelled or forfeited under the 2011 Plan that were carried over to the 2016 Plan totaled 5,152,236 . The 2016 Plan formerly provided for an annual increase in the shares available for issuance, to be added on the first day of each fiscal year, beginning on January 1, 2017, equal to the lesser of (i) five percent ( 5% ) of the outstanding shares of the Company’s ordinary shares on the last day of the immediately preceding fiscal year or (ii) such number of shares determined by the Company’s board of directors or the compensation committee. In August 2018, in connection with the Company's IPO on the Stock Exchange of Hong Kong Limited ("HKEx"), the board of directors of the Company approved an amended and restated 2016 Plan to remove this “evergreen” provision and implement other changes required by the HKEx rules. In December 2018, the board of directors approved a second amended and restated 2016 Plan to increase the number of shares authorized for issuance by 38,553,159 ordinary shares, as well as amend the cap on annual compensation to independent directors and make other changes. The number of shares available for issuance under the 2016 Plan is subject to adjustment in the event of a share split, share dividend or other change in the Company’s capitalization. During the three months ended March 31, 2020 , the Company granted options for 462,449 ordinary shares and restricted share units for 1,880,554 ordinary shares under the 2016 Plan. As of March 31, 2020 , options and restricted share units for ordinary shares outstanding under the 2016 Plan totaled 90,600,885 and 25,109,448 , respectively. 2018 Inducement Equity Plan On June 6, 2018, the board of directors of the Company approved the 2018 Inducement Equity Plan (the “2018 Plan”) and reserved 12,000,000 ordinary shares to be used exclusively for grants of awards to individuals that were not previously employees of the Company or its subsidiaries, as a material inducement to the individual’s entry into employment with the Company or its subsidiaries within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules. The 2018 Plan was approved by the board of directors upon recommendation of the compensation committee, without shareholder approval pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The terms and conditions of the 2018 Plan, and the forms of award agreements to be used thereunder, are substantially similar to the 2016 Plan and the forms of award agreements thereunder. In August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated 2018 Plan to implement changes required by the HKEx rules. During the three months ended March 31, 2020 , the Company did not grant any options or restricted share units under the 2018 Plan. As of March 31, 2020 , options and restricted share units for ordinary shares outstanding under the 2018 Plan totaled 79,404 and 2,228,174 , respectively. 2018 Employee Share Purchase Plan On June 6, 2018, the shareholders of the Company approved the 2018 Employee Share Purchase Plan (the “ESPP”). Initially, 3,500,000 ordinary shares of the Company were reserved for issuance under the ESPP. In August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated ESPP to remove an “evergreen” share replenishment provision originally included in the plan and implement other changes required by the HKEx rules. In December 2018, the shareholders of the Company approved a second amended and restated ESPP to increase the number of shares authorized for issuance by 3,855,315 ordinary shares to 7,355,315 ordinary shares. In June 2019, the board of directors adopted an amendment to revise the eligibility criteria for enrollment in the plan. The ESPP allows eligible employees to purchase the Company’s ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be six months, at a 15% discount to the market price of the Company’s ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to 10% of their eligible earnings, subject to applicable limitations. On February 28, 2020, the Company issued 425,425 ordinary shares to employees for aggregate proceeds of $4,048 under the ESPP. The purchase price of the shares was $123.71 per ADS, or $9.52 per ordinary share, which was discounted in accordance with the terms of the ESPP from the closing price on NASDAQ on February 28, 2020 of $158.35 per ADS, or $12.18 per ordinary share. On August 30, 2019, the Company issued 233,194 ordinary shares to employees for aggregate proceeds of $2,192 under the ESPP. The purchase price of the shares was $122.19 per ADS, or $9.40 per ordinary share, which was discounted in accordance with the terms of the ESPP from the closing price on NASDAQ on August 30, 2019 of $143.75 per ADS, or $11.06 per ordinary share. On February 28, 2019, the Company issued 154,505 ordinary shares to employees for aggregate proceeds of $1,385 under the ESPP. The purchase price of the shares was $116.49 per ADS, or $8.96 per ordinary share, which was discounted in accordance with the terms of the ESPP from the closing price on NASDAQ on February 28, 2019 of $137.05 per ADS, or $10.54 per ordinary share. The following table summarizes total share-based compensation expense recognized for the three months ended March 31, 2020 and 2019 : Three Months Ended March 31, 2020 2019 $ $ Research and development 20,399 15,771 Selling, general and administrative 17,856 10,621 Total 38,255 26,392

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income The movement of accumulated other comprehensive income was as follows: Unrealized Foreign Currency Gains on Translation Available-for-Sale Adjustments Securities Total $ $ $ Balance as of December 31, 2019 (9,291 ) 1,290 (8,001 ) Other comprehensive (loss)/ income before reclassifications (4,245 ) 6,938 2,693 Amounts reclassified from accumulated other comprehensive income — (1,240 ) (1,240 ) Net-current period other comprehensive (loss)/ income (4,245 ) 5,698 1,453 Balance as of March 31, 2020 (13,536 ) 6,988 (6,548 )

Shareholders_ Equity

Shareholders’ Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Shareholders’ Equity	Shareholders’ Equity Share Purchase Agreement On January 2, 2020, the Company sold 15,895,001 ADSs, representing a 20.5% ownership stake in the Company, to Amgen for aggregate cash proceeds of $2,779,241 , or $174.85 per ADS, pursuant to the SPA executed in connection with the Amgen Collaboration Agreement.

Restricted Net Assets

Restricted Net Assets	3 Months Ended
	Mar. 31, 2020
Restricted Net Assets Disclosure [Abstract]
Restricted Net Assets	Restricted Net Assets The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s PRC subsidiaries only out of the subsidiary's retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the condensed consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company’s PRC subsidiaries. In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the board of directors, from the profits determined in accordance with the enterprise’s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s PRC subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits. During the three months ended March 31, 2020 and 2019 , no appropriation to statutory reserves was made because the PRC subsidiaries had substantial losses during these periods. As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least 10% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. Foreign exchange and other regulations in the PRC may further restrict the Company's PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. As of March 31, 2020 and December 31, 2019 , amounts restricted were the net assets of the Company’s PRC subsidiaries, which amounted to $102,494 and $109,633 , respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of March 31, 2020 , the Company had purchase commitments amounting to $117,325 , of which $96,686 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $20,639 related to binding purchase obligations of inventory from BMS. The Company does not have any minimum purchase requirements for inventory from BMS. Capital commitments The Company had capital commitments amounting to $60,645 for the acquisition of property, plant and equipment as of March 31, 2020 , which were mainly for BeiGene Guangzhou Factory’s manufacturing facility in Guangzhou, China. Co-development funding commitment Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000 . The Company is funding its portion of the co-development costs by contributing cash and development services. As of March 31, 2020, the Company's remaining co-development funding commitment was $1,194,000 . Other Business Agreements The Company enters into agreements in the ordinary course of business with contract research organizations ("CROs") to provide research and development services. These contracts are generally cancelable at any time by us with prior written notice. The Company also enters into collaboration agreements with institutions and companies to license intellectual property. The Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with its collaboration agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. These commitments are not recorded on the Company's balance sheet because the achievement and timing of these milestones are not fixed and determinable. When the achievement of these milestones or sales have occurred, the corresponding amounts are recognized in the Company’s financial statements.

Segment and geographic informat

Segment and geographic information	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment and geographic information	Segment and geographic information The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance and allocates resources on a consolidated basis. The Company’s long-lived assets are substantially located in the PRC. Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total net revenues by geographic area are presented as follows: Three Months Ended March 31, 2020 2019 $ $ PRC 51,342 57,421 United States 717 13,268 Other — 7,144 Total 52,059 77,833

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On April 13, 2020, the Company's board of directors adopted an amendment to the 2016 Plan to increase the number of authorized shares by 57,200,000 ordinary shares and to extend the term of the plan through April 13, 2030, subject to approval of the Company's shareholders at the annual meeting to be held on June 17, 2020.

Description of Business, Basi_2

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying condensed consolidated balance sheet as of March 31, 2020 , the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2020 and 2019 , the condensed consolidated statements of cash flows for the three months ended March 31, 2020 and 2019 , and the condensed consolidated statements of shareholders' equity for the three months ended March 31, 2020 and 2019 , and the related footnote disclosures are unaudited. The accompanying unaudited interim financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the "Annual Report"). The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of the operations for the three months ended March 31, 2020 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. The condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Noncontrolling interests are recognized to reflect the portion of the equity of subsidiaries which are not attributable, directly or indirectly, to the controlling shareholders. The Company consolidates its interests in its joint venture, BeiGene Biologics Co., Ltd. ("BeiGene Biologics") and MapKure, LLC, under the voting model and recognizes the minority shareholders' equity interest as a noncontrolling interest in its condensed consolidated financial statements.
Use of estimates	Use of estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company’s revenue arrangements, estimating the fair value of net assets acquired in business combinations, assessing the impairment of long-lived assets, share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.
Recent accounting pronouncements	Recent accounting pronouncements New accounting standards which have been adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses . Subsequently, the FASB issued ASU 2019-05, Financial Instruments- Credit Losses (Topic 326): Targeted Transition Relief and ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments- Credit Losses (collectively, the "Credit Loss ASUs"). The Credit Loss ASUs change the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The Company adopted the standard on January 1, 2020. Based on the composition of the Company's trade receivables and investment portfolio, the adoption of this standard did not have a material impact on the Company’s financial position or results of operations upon adoption. The Company has updated its accounting policy for trade accounts receivable and is providing additional disclosure about its allowance for credit losses, as required by the standard, upon adoption. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement . The update eliminates, modifies, and adds certain disclosure requirements for fair value measurements. The added disclosure requirements and the modified disclosure on the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented. All other changes to disclosure requirements in this update should be applied retrospectively to all periods presented upon their effective date. The Company adopted this standard on January 1, 2020. There was no material impact to the Company's financial position or results of operations upon adoption. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract . This update requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. This guidance should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company adopted this standard on January 1, 2020. There was no material impact to the Company's financial position or results of operations upon adoption. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 . This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Company adopted this standard on January 1, 2020. There was no material impact to the Company's financial position or results of operations upon adoption. New accounting standards which have not yet been adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . This update simplifies the accounting for income taxes as part of the FASB's overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, Income taxes , and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2020, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, and all other amendments should be applied prospectively. The Company is currently evaluating the impact on its financial statements of adopting this guidance. Significant accounting policies For a more complete discussion of the Company’s significant accounting policies and other information, the condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2019 .
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company's current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer's ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased. Except for the changes to the Company’s significant accounting policies related to the adoption of the Credit Loss ASUs, there have been no other material changes to the Company’s significant accounting policies as of and for the three months ended March 31, 2020 , as compared to the significant accounting policies described in the Annual Report.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of assets measured at fair value on a recurring basis	The following tables present the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of March 31, 2020 and December 31, 2019 : Quoted Price in Active Significant Market for Other Significant Identical Observable Unobservable Assets Inputs Inputs As of March 31, 2020 (Level 1) (Level 2) (Level 3) $ $ $ Short-term investments (Note 4): U.S. treasury securities 1,417,097 — — Cash equivalents: U.S. treasury securities 251,505 — — Money market funds 1,144,458 — — Other non-current assets: Equity securities (Note 4) 7,592 4,372 — Total 2,820,652 4,372 — Quoted Price in Active Significant Market for Other Significant Identical Observable Unobservable Assets Inputs Inputs As of December 31, 2019 (Level 1) (Level 2) (Level 3) $ $ $ Short-term investments (Note 4): U.S. treasury securities 364,728 — — Cash equivalents U.S. treasury securities 16,442 — — Money market funds 50,461 — — Total 431,631 — —

Collaborative Arrangements (Tab

Collaborative Arrangements (Tables)	3 Months Ended
	Mar. 31, 2020
Research and Development [Abstract]
Collaboration Agreements	Amounts recorded related to the cash proceeds received from the Amgen collaboration for the three months ended March 31, 2020 were as follows: Three Months Ended March 31, 2020 $ Fair value of equity issued to Amgen 2,162,407 Fair value of research and development cost share liability 616,834 Total cash proceeds 2,779,241 Amounts recorded related to the Company's portion of the co-development funding on the pipeline assets for the three months ended March 31, 2020 were as follows: Three Months Ended March 31, 2020 $ Research and development expense 28,366 Amortization of research and development cost share liability 27,634 Total amount due to Amgen for BeiGene's portion of the development funding 56,000 Total amount of development funding payable in cash 56,000 Total amount of development funding paid with development services — Remaining portion of development funding cap at March 31, 2020 1,194,000 At March 31, 2020 , the research and development cost share liability recorded in the Company's balance sheet was as follows: As of March 31, 2020 $ Research and development cost share liability, current portion 128,672 Research and development cost share liability, non-current portion 460,528 Total research and development cost share liability 589,200
Schedule of total collaboration revenue recognized	The following table summarizes total collaboration revenue recognized related to the BMS collaboration for the three months ended March 31, 2020 and 2019 : Three Months Ended March 31, 2020 2019 $ $ Reimbursement of research and development costs — 18,174 Research and development service revenue — 2,238 Total — 20,412 Three Months Ended March 31, 2020 2019 Research and development payments to Collaboration Partners $ $ Upfront payments 43,000 10,000 Milestone payments 5,000 — Total 48,000 10,000 three months ended March 31, 2020 and 2019 . Three Months Ended March 31, 2020 2019 $ $ Product revenue – gross 53,188 58,536 Less: Rebates and sales returns (1,129 ) (1,115 ) Product revenue – net 52,059 57,421 The following table disaggregates net product sales by product for the three months ended March 31, 2020 and March 31, 2019 : Three Months Ended March 31, 2020 2019 $ $ Tislelizumab 20,526 — BRUKINSA ™ 717 — ABRAXANE ® 17,145 27,134 REVLIMID ® 7,628 23,584 VIDAZA ® 6,043 6,703 Total net product revenue 52,059 57,421

Restricted Cash and Investmen_2

Restricted Cash and Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Schedule of short-term investments	Short-term investments as of March 31, 2020 consisted of the following available-for-sale debt securities: Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) $ $ $ $ U.S. treasury securities 1,410,129 6,968 — 1,417,097 Total 1,410,129 6,968 — 1,417,097 Short-term investments as of December 31, 2019 consisted of the following available-for-sale debt securities: Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) $ $ $ $ U.S. treasury securities 363,440 1,288 — 364,728 Total 363,440 1,288 — 364,728

Inventories x (Tables)

Inventories x (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	The Company’s inventory balance consisted of the following: As of March 31, December 31, 2020 2019 $ $ Work in process 444 — Finished goods 28,331 28,553 Total inventories 28,775 28,553

Property, plant and equipment (

Property, plant and equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of components of property and equipment	Property, plant and equipment are recorded at cost and consisted of the following: As of March 31, December 31, 2020 2019 $ $ Laboratory equipment 49,059 47,154 Leasehold improvements 23,866 24,008 Building 107,992 109,514 Manufacturing equipment 65,123 62,775 Software, electronics and office equipment 14,688 14,705 Property, plant and equipment, at cost 260,728 258,156 Less accumulated depreciation (43,375 ) (36,709 ) Construction in progress 22,978 20,955 Property, plant and equipment, net 240,331 242,402

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible assets outstanding	Intangible assets as of March 31, 2020 and December 31, 2019 are summarized as follows: As of March 31, 2020 December 31, 2019 Gross Gross carrying Accumulated Intangible carrying Accumulated Intangible amount amortization assets, net amount amortization assets, net $ $ $ $ $ $ Finite-lived intangible assets: Product distribution rights 7,500 (1,937 ) 5,563 7,500 (1,750 ) 5,750 Trading license 816 (816 ) — 816 (720 ) 96 Total finite-lived intangible assets 8,316 (2,753 ) 5,563 8,316 (2,470 ) 5,846

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Allowance for credit receivable rollforward	The roll-forward of the allowance for credit losses related to trade accounts receivable for the three months ended March 31, 2020 consists of the following activity: Allowance for Credit Losses $ Balance as of December 31, 2019 — Current period provision for expected credit losses 2,022 Amounts written-off — Recoveries of amounts previously written-off — Balance as of March 31, 2020 2,022
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consist of the following: As of March 31, December 31, 2020 2019 $ $ Prepaid research and development costs 75,867 69,715 Prepaid taxes 17,392 9,498 Other receivables 6,414 — Interest receivable 5,941 1,932 Prepaid insurance 4,298 — Prepaid manufacturing costs 3,525 — Other 12,875 9,093 Total 126,312 90,238
Schedule of other non-current assets	Other non-current assets consist of the following: As of March 31, December 31, 2020 2019 $ $ Goodwill 109 109 Prepayment of property and equipment 20,421 10,289 Prepayment of facility capacity expansion activities (1) 25,963 24,881 Prepaid VAT 32,396 29,967 Rental deposits and other 3,397 3,209 Long-term investment (Note 4) 11,964 — Total 94,250 68,455 (1) Represents payments for facility expansions under commercial supply agreements. The payments will provide future benefit to the Company through credits on future supply purchases as further described in Note 7.
Schedule of accrued expenses and other payables	Accrued expenses and other payables consist of the following: As of March 31, December 31, 2020 2019 $ $ Compensation related 27,272 54,156 External research and development activities related 53,428 62,794 Development funding payable- Amgen 56,000 — Commercial activities 18,522 25,645 Income tax and other taxes 11,944 9,648 Sales rebates and returns related 4,014 3,198 Professional fees and other 8,151 8,115 Total 179,331 163,556
Schedule of other long-term liabilities	Other long-term liabilities consist of the following: As of March 31, December 31, 2020 2019 $ $ Deferred government grant income 45,134 46,391 Other 171 171 Total 45,305 46,562

Product Revenue (Tables)

Product Revenue (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Schedule of net product sales	The following table summarizes total collaboration revenue recognized related to the BMS collaboration for the three months ended March 31, 2020 and 2019 : Three Months Ended March 31, 2020 2019 $ $ Reimbursement of research and development costs — 18,174 Research and development service revenue — 2,238 Total — 20,412 Three Months Ended March 31, 2020 2019 Research and development payments to Collaboration Partners $ $ Upfront payments 43,000 10,000 Milestone payments 5,000 — Total 48,000 10,000 three months ended March 31, 2020 and 2019 . Three Months Ended March 31, 2020 2019 $ $ Product revenue – gross 53,188 58,536 Less: Rebates and sales returns (1,129 ) (1,115 ) Product revenue – net 52,059 57,421 The following table disaggregates net product sales by product for the three months ended March 31, 2020 and March 31, 2019 : Three Months Ended March 31, 2020 2019 $ $ Tislelizumab 20,526 — BRUKINSA ™ 717 — ABRAXANE ® 17,145 27,134 REVLIMID ® 7,628 23,584 VIDAZA ® 6,043 6,703 Total net product revenue 52,059 57,421
Schedule of accrued sales rebates and returns	The following table presents the roll-forward of accrued sales rebates and returns for the three months ended March 31, 2020 and March 31, 2019 : Sales Rebates and Returns $ Balance as of December 31, 2019 4,749 Accrual 1,115 Payments (2,498 ) Balance as of March 31, 2019 3,366 Balance as of December 31, 2019 3,198 Accrual 1,129 Payments (313 ) Balance as of March 31, 2020 4,014

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of the calculation of basic and diluted net (loss) income per ordinary share	Loss per share was calculated as follows: Three Months Ended March 31, 2020 2019 $ $ Numerator: Net loss attributable to BeiGene, Ltd. (363,735 ) (167,640 ) Denominator: Weighted average shares outstanding, basic and diluted 1,005,347,581 774,750,255 Net loss per share attributable to BeiGene, Ltd., basic and diluted (0.36 ) (0.22 )

Share-Based Compensation Expe_2

Share-Based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of total compensation cost recognized	The following table summarizes total share-based compensation expense recognized for the three months ended March 31, 2020 and 2019 : Three Months Ended March 31, 2020 2019 $ $ Research and development 20,399 15,771 Selling, general and administrative 17,856 10,621 Total 38,255 26,392

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of accumulated other comprehensive income	The movement of accumulated other comprehensive income was as follows: Unrealized Foreign Currency Gains on Translation Available-for-Sale Adjustments Securities Total $ $ $ Balance as of December 31, 2019 (9,291 ) 1,290 (8,001 ) Other comprehensive (loss)/ income before reclassifications (4,245 ) 6,938 2,693 Amounts reclassified from accumulated other comprehensive income — (1,240 ) (1,240 ) Net-current period other comprehensive (loss)/ income (4,245 ) 5,698 1,453 Balance as of March 31, 2020 (13,536 ) 6,988 (6,548 )

Segment and geographic inform_2

Segment and geographic information (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of net product revenues by geographic area	: Three Months Ended March 31, 2020 2019 $ $ PRC 51,342 57,421 United States 717 13,268 Other — 7,144 Total 52,059 77,833

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Assets:
Short-term investments	$ 1,417,097,000	$ 364,728,000
U.S. treasury securities
Assets:
Short-term investments	1,417,097,000	364,728,000
Recurring basis
Liabilities:
Liabilities measured and recorded at fair value	0	0
Recurring basis | (Level 1)
Assets:
Equity securities (Note 4)	7,592,000
Total	2,820,652,000	431,631,000
Recurring basis | (Level 1) | Money market funds
Assets:
Cash equivalents:	1,144,458,000	50,461,000
Recurring basis | (Level 1) | U.S. treasury securities
Assets:
Short-term investments	1,417,097,000	364,728,000
Cash equivalents:	251,505,000	16,442,000
Recurring basis | (Level 2)
Assets:
Equity securities (Note 4)	4,372,000
Total	4,372,000	0
Recurring basis | (Level 2) | Money market funds
Assets:
Cash equivalents:	0	0
Recurring basis | (Level 2) | U.S. treasury securities
Assets:
Short-term investments	0	0
Cash equivalents:	0	0
Recurring basis | (Level 3)
Assets:
Equity securities (Note 4)	0
Total	0	0
Recurring basis | (Level 3) | Money market funds
Assets:
Cash equivalents:	0	0
Recurring basis | (Level 3) | U.S. treasury securities
Assets:
Short-term investments	0	0
Cash equivalents:	$ 0	$ 0

Collaborative Arrangements - Am

Collaborative Arrangements - Amgen (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 02, 2020	Mar. 31, 2020
Common Stock
Research and Development Arrangement, Contract to Perform for Others
Share price, ADS (in dollars per share)	$ 132.74
Proceeds from ADS shares	$ 2,109,902
Beigene | Amgen, Inc
Research and Development Arrangement, Contract to Perform for Others
Minority interest in investment (as a percent)	20.50%
Amgen, Inc
Research and Development Arrangement, Contract to Perform for Others
Maximum cash and development services commitment	$ 1,250,000
Shares issued (in shares)	15,895,001
Per share acquisition price (usd per share)	$ 174.85
Payments to acquire equity interest	$ 2,779,241
Fair value of equity issued to Amgen		$ 2,162,407
Fair value of research and development cost share liability	$ 601,857	$ 616,834

Collaborative Arrangements - De

Collaborative Arrangements - Details of Proceeds From Transaction (Details) - Amgen, Inc - USD ($) $ in Thousands	Jan. 02, 2020	Mar. 31, 2020
Research and Development Arrangement, Contract to Perform for Others
Fair value of equity issued to Amgen		$ 2,162,407
Fair value of research and development cost share liability	$ 601,857	616,834
Payments to Acquire Businesses, Net of Cash Acquired		$ 2,779,241

Collaborative Arrangements - Fu

Collaborative Arrangements - Funding Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Research and Development Arrangement, Contract to Perform for Others
Research and development expense	$ 304,302	$ 178,351
Total amount of development funding payable in cash	56,000		$ 0
Amgen, Inc
Research and Development Arrangement, Contract to Perform for Others
Research and development expense	28,366
Amortization of research and development cost share liability	27,634
Total amount due to Amgen for BeiGene's portion of the development funding	56,000
Total amount of development funding payable in cash	56,000
Total amount of development funding paid with development services	0
Remaining portion of development funding cap at March 31, 2020	$ 1,194,000

Collaborative Arrangements - Fi

Collaborative Arrangements - Financing Liability (Details) - Amgen, Inc $ in Thousands	Mar. 31, 2020USD ($)
Research and Development Arrangement, Contract to Perform for Others
Research and development cost share liability, current portion	$ 128,672
Research and development cost share liability, non-current portion	460,528
Total research and development cost share liability	$ 589,200

Collaborative Arrangements - Co

Collaborative Arrangements - Collaboration Revenue Recognized (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues
Revenues	$ 52,059	$ 77,833
Collaboration
Revenues
Revenues	0	20,412
Reimbursement of research and development costs
Revenues
Revenues	0	18,174
Research and development service revenue
Revenues
Revenues	$ 0	$ 2,238

Collaborative Arrangements - _2

Collaborative Arrangements - Collaboration Revenue Recognized Narratives (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Research and Development Arrangement, Contract to Perform for Others
Revenues	$ 52,059	$ 77,833
Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others
Revenues	0	20,412
Reimbursement of research and development costs
Research and Development Arrangement, Contract to Perform for Others
Revenues	0	18,174
Research and development service revenue
Research and Development Arrangement, Contract to Perform for Others
Revenues	$ 0	2,238
Deferred revenue recognized		$ 2,238

Collaborative Arrangements - In

Collaborative Arrangements - In Licensing Agreements (Details) - USD ($) $ in Thousands	Feb. 13, 2020	Mar. 31, 2020	Mar. 31, 2019
Research and Development Arrangement, Contract to Perform for Others
Upfront payments	$ 40,000	$ 43,000	$ 10,000
Milestone payments		5,000	0
Total		48,000	$ 10,000
EUSA Pharma
Research and Development Arrangement, Contract to Perform for Others
Maximum milestone payments		$ 160,000

Restricted Cash and Investmen_3

Restricted Cash and Investments - Restricted Cash (Details) $ in Thousands	Mar. 31, 2020USD ($)
Investments, Debt and Equity Securities [Abstract]
Restricted cash	$ 2,717

Restricted Cash and Investmen_4

Restricted Cash and Investments - Tabular Disclosure (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Short-term investments
Available-for-sale securities, amortized cost	$ 1,410,129	$ 363,440
Available-for-sale securities, gross unrealized gains	6,968	1,288
Available-for-sale securities. gross unrealized losses	0	0
Short-term investments	1,417,097	364,728
U.S. treasury securities
Short-term investments
Available-for-sale securities, amortized cost	1,410,129	363,440
Available-for-sale securities, gross unrealized gains	6,968	1,288
Available-for-sale securities. gross unrealized losses	0	0
Short-term investments	$ 1,417,097	$ 364,728

Restricted Cash and Investmen_5

Restricted Cash and Investments - Equity Method Investment (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2020	Mar. 31, 2020	Mar. 31, 2019
Schedule of Investments
Purchases of investments		$ 1,307,179	$ 487,354
Gains from equity investments		6,964	$ 0
Leap Therapeutic, Inc
Schedule of Investments
Equity method investments (percent)	13.40%
Equity method investments, including warrants (percent)	23.70%
Gains from equity investments		6,964
Leap Therapeutic, Inc | Series B preferred stock
Schedule of Investments
Purchases of investments	$ 5,000
Warrants		4,372
Leap Therapeutic, Inc | Common Stock
Schedule of Investments
Equity investment		$ 7,592

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Work in process	$ 444	$ 0
Finished goods	28,331	28,553
Inventories	$ 28,775	$ 28,553

Property, plant and equipment -

Property, plant and equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property and equipment
Property, plant and equipment, at cost	$ 260,728	$ 258,156
Less accumulated depreciation	(43,375)	(36,709)
Property, plant and equipment, net	240,331	242,402
Laboratory equipment
Property and equipment
Property, plant and equipment, at cost	49,059	47,154
Leasehold improvements
Property and equipment
Property, plant and equipment, at cost	23,866	24,008
Building
Property and equipment
Property, plant and equipment, at cost	107,992	109,514
Manufacturing equipment
Property and equipment
Property, plant and equipment, at cost	65,123	62,775
Software, electronics and office equipment
Property and equipment
Property, plant and equipment, at cost	14,688	14,705
Construction in progress
Property and equipment
Property, plant and equipment, at cost	$ 22,978	$ 20,955

Property, plant and equipment_2

Property, plant and equipment - Depreciation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property and equipment
Depreciation expense	$ 7,467	$ 3,085

Guangzhou Biologics Business (D

Guangzhou Biologics Business (Details) $ in Thousands	Apr. 14, 2017CNY (¥)	Mar. 31, 2017CNY (¥)asset	Mar. 31, 2020USD ($)	Dec. 31, 2017	Jun. 30, 2017CNY (¥)	Dec. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 21, 2018	Mar. 07, 2017CNY (¥)
Organization
Cash and cash equivalents | $			$ 1,957,101			$ 618,011	$ 764,492
Restricted cash | $			$ 2,717
Shareholder Loan | Convertible Debt | Investor
Organization
Face amount									¥ 900,000,000
Shareholder loan	¥ 900,000,000
BeiGene Biologics Co., Ltd. (BeiGene Biologics)
Organization
Ownership percentage immediately after transaction (as a percent)			95.00%
BeiGene (Hong Kong) Co., Limited.(“BeiGene HK”)
Organization
Cash capital contribution, agreed amount		¥ 200,000,000
Minimum number of biologics assets to be contributed | asset		1
BeiGene (Hong Kong) Co., Limited.(“BeiGene HK”) | Contributions One
Organization
Cash capital contribution					¥ 137,830,000
BeiGene (Hong Kong) Co., Limited.(“BeiGene HK”) | Contributions Two
Organization
Cash capital contribution					¥ 2,415,000
BeiGene (Hong Kong) Co., Limited.(“BeiGene HK”) | BeiGene Biologics Co., Ltd. (BeiGene Biologics)
Organization
Ownership percentage immediately after transaction (as a percent)		95.00%
BeiGene (Hong Kong) Co., Limited.(“BeiGene HK”) | BeiGene (Shanghai) Co., Ltd. (“BeiGene (Shanghai)”)
Organization
Ownership percentage immediately after transaction (as a percent)				95.00%
Ownership percentage immediately before transaction (as a percent)				100.00%
GET
Organization
Cash capital contribution, agreed amount		¥ 100,000,000
Capital contribution from noncontrolling interest	100,000,000
GET | BeiGene Biologics Co., Ltd. (BeiGene Biologics)
Organization
Ownership percentage immediately after transaction (as a percent)			5.00%
Minority interest in investment (as a percent)		5.00%
BeiGene Biologics Co., Ltd. (BeiGene Biologics)
Organization
Cash and cash equivalents | $			$ 83,126
Restricted cash | $			$ 1,961
BeiGene Biologics Co., Ltd. (BeiGene Biologics) | Shareholder Loan | Convertible Debt | Investor
Organization
Face amount									¥ 900,000,000
Shareholder loan	¥ 900,000,000
BeiGene (Guangzhou) Co., Ltd. (“BeiGene Guangzhou”) | Baiji Shenzhou (Guangzhou) Pharmaceuticals Co., Ltd.
Organization
Ownership percentage (as a percent)								100.00%

Intangible Assets - Intangible

Intangible Assets - Intangible Assets Outstanding (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Intangible assets
Gross carrying amount	$ 8,316	$ 8,316
Accumulated amortization	(2,753)	(2,470)
Intangible assets, net	5,563	5,846
Product distribution rights
Intangible assets
Gross carrying amount	7,500	7,500
Accumulated amortization	(1,937)	(1,750)
Intangible assets, net	5,563	5,750
Trading license
Intangible assets
Gross carrying amount	816	816
Accumulated amortization	(816)	(720)
Intangible assets, net	$ 0	$ 96

Intangible Assets - Useful Life

Intangible Assets - Useful Life (Details)	3 Months Ended
	Mar. 31, 2020
Product distribution rights
Other intangible assets
Useful life	10 years

Intangible Assets - Amortizatio

Intangible Assets - Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Intangible assets
Amortization of intangible assets	$ 283	$ 331

Intangible Assets - Expected Am

Intangible Assets - Expected Amortization Expense (Details) $ in Thousands	Mar. 31, 2020USD ($)
Expected amortization expense
Remainder of 2020	$ 563
2021	750
2022	750
2023	750
2024	750
2025 and thereafter	$ 2,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income taxes
Income tax expense	$ 1,554	$ 519
Increase in income taxes receivable	5,586
Unrecognized tax benefits	5,003
Increase in uncertain tax position	$ 369

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Allowance for credit losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accounts Receivable, Allowance for Credit Loss
Balance as of December 31, 2019	$ 0
Current period provision for expected credit losses	2,022	$ 0
Amounts written-off	0
Recoveries of amounts previously written-off	0
Balance as of March 31, 2020	$ 2,022

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Prepaid expenses and other current assets:
Prepaid research and development costs	$ 75,867	$ 69,715
Prepaid taxes	17,392	9,498
Other receivables	6,414	0
Interest receivable	5,941	1,932
Prepaid insurance	4,298	0
Prepaid manufacturing costs	3,525	0
Other	12,875	9,093
Total	$ 126,312	$ 90,238

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Other non-current assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other non-current assets:
Goodwill	$ 109	$ 109
Prepayment of property and equipment	20,421	10,289
Prepayment of facility capacity expansion activities	25,963	24,881
Prepaid VAT	32,396	29,967
Rental deposits and other	3,397	3,209
Long-term investment (Note 4)	11,964	0
Total	$ 94,250	$ 68,455

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Accrued expenses and other payables (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued expenses and other payables
Compensation related	$ 27,272	$ 54,156
External research and development activities related	53,428	62,794
Total amount of development funding payable in cash	56,000	0
Commercial activities	18,522	25,645
Income tax and other taxes	11,944	9,648
Sales rebates and returns related	4,014	3,198
Professional fees and other	8,151	8,115
Total	$ 179,331	$ 163,556

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information - Other long-term liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other long-term liabilities
Deferred government grant income	$ 45,134	$ 46,391
Other	171	171
Total	$ 45,305	$ 46,562

Bank Loans (Details)

Bank Loans (Details) $ in Thousands	Jan. 13, 2020CNY (¥)	Apr. 04, 2018CNY (¥)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2020CNY (¥)	Jan. 19, 2020CNY (¥)
Long-term bank loan
Proceeds from long-term bank loan			$ 0	$ 36,695
Loans Payable | China Industrial Bank
Long-term bank loan
Short-term debt			11,298		$ 11,298
Long Term Bank Loan, Jan 2021 | Loans Payable | China Industrial Bank
Long-term bank loan
Debt instrument term (in years)	1 year
Face amount | ¥	¥ 200,000,000
Fixed annual interest rate (as a percent)	5.60%
Long Term Bank Loan, Jan 2021 II | Loans Payable | China Industrial Bank
Long-term bank loan
Face amount | ¥							¥ 80,000,000
Loans Payable
Long-term bank loan
Interest expense			1,719	941
Interest capitalized			$ 66	$ 641
Loans Payable | Long Term Bank Loan April 2018
Long-term bank loan
Debt instrument term (in years)		9 years
Loans Payable | Long Term Bank Loan April 2018 | China Construction Bank
Long-term bank loan
Face amount | ¥		¥ 580,000,000
Proceeds from long-term bank loan					$ 81,913	¥ 580,000,000
Fixed annual interest rate (as a percent)			4.90%		4.90%

Shareholder Loan (Details)

Shareholder Loan (Details) - Shareholder Loan - Investor - Convertible Debt $ in Thousands	Apr. 14, 2017CNY (¥)	Mar. 07, 2017CNY (¥)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Shareholder Loan
Face amount | ¥		¥ 900,000,000
Shareholder loan | ¥	¥ 900,000,000
Shareholder loan interest rate (as a percent)		8.00%
Debt instrument term (in years)	72 months
Interest expense incurred due to a related party | $			$ 2,572	$ 2,645
Interest capitalized | $			$ 0	$ 788

Product Revenue - Product Sales

Product Revenue - Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues
Product revenue – net	$ 52,059	$ 77,833
Product
Revenues
Product revenue – gross	53,188	58,536
Less: Rebates and sales returns	(1,129)	(1,115)
Product revenue – net	52,059	57,421
Product | Tislelizumab
Revenues
Product revenue – net	20,526	0
Product | BRUKINSA™
Revenues
Product revenue – net	717	0
Product | ABRAXANE®
Revenues
Product revenue – net	17,145	27,134
Product | REVLIMID®
Revenues
Product revenue – net	7,628	23,584
Product | VIDAZA®
Revenues
Product revenue – net	$ 6,043	$ 6,703

Product Revenue - Accrued Sales

Product Revenue - Accrued Sales Rebates and Returns (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accrued Sales Rebates and Returns
Beginning balance	$ 3,198
Ending balance	4,014
Product
Accrued Sales Rebates and Returns
Beginning balance	3,198	$ 4,749
Accrual	1,129	1,115
Payments	(313)	(2,498)
Ending balance	$ 4,014	$ 3,366

Loss Per Share (Details)

Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Numerator:
Net loss attributable to BeiGene, Ltd.	$ (363,735)	$ (167,640)
Denominator:
Weighted-average shares outstanding, basic and diluted (shares)	1,005,347,581	774,750,255
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	$ (0.36)	$ (0.22)

Share-Based Compensation Expe_3

Share-Based Compensation Expense - Share Options and Incentive Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 28, 2020	Aug. 30, 2019	Feb. 28, 2019	Jun. 06, 2018	Dec. 31, 2018	Mar. 31, 2020	Dec. 31, 2019	Jan. 14, 2016
2016 Plan
Share-based compensation
Number of shares reserved and available for issuance (in shares)								65,029,595
Automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares (as a percent)						5.00%
Increase in ordinary shares authorized (in shares)					38,553,159
2016 Plan | Share options
Share-based compensation
Granted (in shares)						462,449
Number of options outstanding (in shares)						90,600,885
2016 Plan | Restricted Share Units (RSUs)
Share-based compensation
Granted (in shares)						1,880,554
Number of options outstanding (in shares)						25,109,448
2011 Plan
Share-based compensation
Shares cancelled or forfeited (in shares)						5,152,236
2018 Plan
Share-based compensation
Number of shares reserved and available for issuance (in shares)				12,000,000
2018 Plan | Share options
Share-based compensation
Number of options outstanding (in shares)						79,404
2018 Plan | Restricted Share Units (RSUs)
Share-based compensation
Number of options outstanding (in shares)						2,228,174
ESPP
Share-based compensation
Number of shares reserved and available for issuance (in shares)				3,500,000			7,355,315
Increase in ordinary shares authorized (in shares)					3,855,315
Discount on purchase price of common stock (as a percent)				15.00%
Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)				10.00%
Shares issued in period ( in shares)	425,425	233,194	154,505
Proceeds from shares issued	$ 4,048	$ 2,192	$ 1,385
Share prices of ADS shares issues (in dollars per share)	$ 123.71	$ 122.19	$ 116.49
Exercise price of shares issues (in dollars per share)	9.52	9.40	8.96
Share price, ADS (in dollars per share)	158.35	143.75	137.05
Share price (in dollars per share)	$ 12.18	$ 11.06	$ 10.54

Share-Based Compensation Expe_4

Share-Based Compensation Expense - Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based compensation
Compensation expense	$ 38,255	$ 26,392
Research and development
Share-based compensation
Compensation expense	20,399	15,771
Selling, general and administrative
Share-based compensation
Compensation expense	$ 17,856	$ 10,621

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Movement in accumulated other comprehensive loss
Balance at the beginning of period	$ 978,355
Other comprehensive (loss)/ income before reclassifications	2,693
Amounts reclassified from accumulated other comprehensive income	(1,240)
Other comprehensive income, net of tax of nil	1,453
Balance at the end of period	2,827,056
Accumulated Other Comprehensive Income
Movement in accumulated other comprehensive loss
Balance at the beginning of period	(8,001)
Balance at the end of period	(6,548)
Foreign Currency Translation Adjustments
Movement in accumulated other comprehensive loss
Balance at the beginning of period	(9,291)
Other comprehensive (loss)/ income before reclassifications	(4,245)
Amounts reclassified from accumulated other comprehensive income	0
Other comprehensive income, net of tax of nil	(4,245)
Balance at the end of period	(13,536)
Unrealized Gain on available-for-Sale Securities
Movement in accumulated other comprehensive loss
Balance at the beginning of period	1,290
Other comprehensive (loss)/ income before reclassifications	6,938
Amounts reclassified from accumulated other comprehensive income	(1,240)
Other comprehensive income, net of tax of nil	5,698
Balance at the end of period	$ 6,988

Shareholders_ Equity - Follow-o

Shareholders’ Equity - Follow-on public offerings (Details) $ / shares in Units, $ in Thousands	Jan. 02, 2020USD ($)$ / sharesshares
Amgen, Inc | Beigene
Shareholders' equity
Minority interest in investment (as a percent)	20.50%
Amgen, Inc
Shareholders' equity
Shares issued (in shares) | shares	15,895,001
Payments to acquire equity interest | $	$ 2,779,241
Per share acquisition price (usd per share) | $ / shares	$ 174.85

Restricted Net Assets (Details)

Restricted Net Assets (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Segment Reporting Information
Minimum required statutory reserve of annual after-tax profit (as a percent)	10.00%
Required statutory reserve as a percentage of registered capital (as a percent)	50.00%
Appropriation to statutory reserves	$ 0		$ 0
China
Segment Reporting Information
Restricted net assets	$ 102,494,000	$ 109,633,000

Commitments and Contingencies -

Commitments and Contingencies - Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Jan. 02, 2020
Purchase and Capital commitments
Purchase commitments	$ 117,325
Inventories
Purchase and Capital commitments
Purchase commitments	20,639
Minimum Purchase Commitments For Supply Purchased
Purchase and Capital commitments
Purchase commitments	96,686
Capital Addition Purchase Commitments
Purchase and Capital commitments
Purchase commitments	60,645
Amgen, Inc
Purchase and Capital commitments
Maximum cash and development services commitment		$ 1,250,000
Remaining portion of development funding	$ 1,194,000

Segment and geographic inform_3

Segment and geographic information - General Information (Details)	3 Months Ended
	Mar. 31, 2020segment
Segment information
Number of operating segments	1

Segment and geographic inform_4

Segment and geographic information - Tabular Disclosure (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net product revenues by geographic area
Revenues	$ 52,059	$ 77,833
PRC
Net product revenues by geographic area
Revenues	51,342	57,421
United States
Net product revenues by geographic area
Revenues	717	13,268
Other
Net product revenues by geographic area
Revenues	$ 0	$ 7,144

Subsequent Event (Details)

Subsequent Event (Details)	Apr. 13, 2020shares
Subsequent Event
Subsequent Event
Increase in shares authorized (shares)	57,200,000